The “Hopp Children’s Cancer Center at the NCT Heidelberg” (KiTZ) is a joint initiative of Heidelberg University Hospital and the German Cancer Research Center (DKFZ).
Heidelberg, March, 1st 2018. Up to now, comprehensive molecular-genetic data analyses in pediatric oncology have been rare because patient numbers are comparatively small. However, they would be urgently needed in order to further improve the survival rates of children suffering from cancer. About 20 percent of the young patients still die from the disease. In addition, findings from research on cancer in adults cannot be translated readily to children and adolescents.
Charting the genetic repertoire of pediatric cancer
Heidelberg scientists from the KiTZ, in collaboration with colleagues from the DKFZ, DKTK, NCT and Heidelberg University Hospital as well as specialized research teams from the Society for Pediatric Oncology and Hematology (GPOH), have studied the genetic repertoire of childhood cancer. With the goal of identifying novel approaches for diagnosis and treatment of cancer in children, the investigators used the most advanced DNA sequencing technology and comprehensive data analysis to take a very close look at point mutations in DNA as well as larger structural changes in 961 tumors of 24 different types of cancer.
“It turned out in about half of the patients that genetic alterations affect sites in the genome that are potential targets for so-called targeted anticancer drugs,” said Marc Zapatka,, group leader of Bioinformatics at the Molecular Genetics Department of the DKFZ. Stefan Pfister, scientist at the DKFZ, attending physician at Heidelberg University Hospital and director of the preclinical program at KiTZ, added: “This is a very encouraging result because it means that we might already have agents that target these specific sites and, therefore, might be treatment options for the affected patients.” Pfister continued: “Most of these drugs have not yet been tested for children. It remains to be seen whether they are also safe and effective in young patients.”
In approximately seven percent of all cases, the scientists found genomic alterations that are suspected to have played a role in the development of cancer in these patients. These so-called germline mutations can either be inherited from a parent or form at the very beginning of embryonic development and, therefore, are present in every single body cell of a patient. They are transmitted to the next generation of offspring. Patients with heritable forms of cancer need special attention, because they often need to be treated differently from patients with the same type of cancer who do not have a heritable predisposition.
“Compared to tumors in adults, the investigations revealed large variations in the type and incidence of mutated genes,” said Lukas Chavez, who works at the KiTZ and is a group leader at DKFZ’s Pediatric Neurooncology Department. “This confirms once more that tumor development proceeds in fundamentally different ways in children compared to adults,” Pfister commented. “And it also shows us that we have to go about developing targeted therapies for children differently than for adults. In many cases, we may also need drugs that are specially developed for children.”
The data are freely available at www.pedpancan.com. “We think that our data represent a valuable resource for research in pediatric oncology,” said Pfister. “Therefore, we are pleased that other research groups can also use them in order to enhance the curative chances for our young cancer patients.”
The project has received major support from the German Cancer Consortium (DKTK), the German Cancer Aid (Deutsche Krebshilfe) and the German Childhood Cancer Foundation (Deutsche Kinderkrebsstiftung).
Original publication:
Gröbner et al. The landscape of genomic alterations across childhood cancers. In: NATURE, Online publication 28th February 2018; DOI: 10.1038/nature25480
